サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1757797

おたふくかぜワクチンの世界市場

Mumps Vaccines

出版日
ページ情報
英文 288 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=145.63円
おたふくかぜワクチンの世界市場
出版日: 2025年06月27日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 288 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

おたふくかぜワクチンの世界市場は2030年までに9億9,350万米ドルに達する見込み

2024年に6億5,050万米ドルと推定されるおたふくかぜワクチンの世界市場は、2030年には9億9,350万米ドルに達し、分析期間2024-2030年のCAGRは7.3%で成長すると予測されます。本レポートで分析したセグメントの1つである一価は、CAGR 9.0%を記録し、分析期間終了時には4億8,350万米ドルに達すると予測されます。コンビネーショナルセグメントの成長率は、分析期間中CAGR 4.8%と推定されます。

米国市場は1億7,720万米ドルと推定、中国はCAGR 11.7％で成長予測

米国のおたふくかぜワクチン市場は、2024年に1億7,720万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを11.7%として、2030年までに2億1,260万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.5%と7.1%と予測されています。欧州では、ドイツがCAGR 4.9%で成長すると予測されています。

世界のおたふくかぜワクチン市場- 主要動向と促進要因のまとめ

なぜおたふくかぜワクチンは世界の公衆衛生戦略にとって重要なのか？

おたふくかぜワクチンは、唾液腺の腫れ、発熱、頭痛、場合によっては髄膜炎、睾丸炎、難聴などの合併症を特徴とする伝染性のウイルス性疾患である流行性耳下腺炎の発生を予防する上で極めて重要な役割を果たしています。MMR（麻疹、おたふくかぜ、風疹）混合ワクチンの一部としてのみ接種されるこのワクチンは、導入以来、世界のおたふくかぜの発生率を大幅に減少させてきました。しかし、ワクチン接種率が高い集団でも最近集団感染が発生したことから、接種率の向上と長期的な免疫の改善に再び注目が集まっています。

多くの国の定期予防接種プログラムでは、おたふくかぜワクチンを幼児期に2回接種し、流行しやすい地域では思春期または成人期にブースター接種を行うことが多いです。より広範なウイルス封じ込め戦略においておたふくかぜワクチンは重要な役割を担っているため、個人の予防だけでなく、特に学校、大学、軍事施設、その他の高密度環境において、地域レベルの集団免疫を維持するためにも不可欠です。

有効性と接種率の課題に対処するために、ワクチン技術はどのように進化しているのか？

現在使用されているほとんどの弱毒生ウイルス製剤は、主にジェリルリン、レニングラード・ザグレブ、ウラベなどの株に由来するものです。効果的ではあるが、これらの菌株は免疫原性や防御期間にばらつきがあり、長期的な効果や集団レベルのアウトブレイク回復力に影響を及ぼす可能性があります。そのため、新たな弱毒化技術、菌株の改良、アジュバントシステムの強化などを通じて、ワクチンの有効性を向上させるための調査が続けられています。

公衆衛生当局の中には、特に抗体価が低下している集団において、おたふくかぜに特異的な免疫を増強するための一価または二価のブースターの開発を検討しているところもあります。低資源環境でのワクチン摂取を改善するため、耐熱性製剤や経鼻投与システムの開発が進められています。さらに、ゲノムサーベイランスは、流行中のおたふくかぜ株の監視やワクチン株とおたふくかぜ株の一致の評価に利用されており、予防接種に関する推奨事項の更新や接種スケジュールの改善に役立っています。

市場の需要を牽引している地域と人口層は？

予防接種プログラムが確立している高所得国は、特に小児科のスケジュールや就学要件を通じて、引き続きMMRワクチンの需要を牽引しています。しかし、大学やヘルスケアの現場でのおたふくかぜの流行を受けて、成人のブースタープログラムも拡大しています。新興経済国では、定期予防接種の普及拡大への取り組みが、南米、サハラ以南のアフリカ、ラテンアメリカを含むMMRワクチンの一次需要を押し上げています。

紛争地域やヘルスケアのインフラが寸断された地域の住民も、国際援助や集団予防接種キャンペーンを通じて、おたふくかぜワクチン接種の優先ターゲットとなっています。季節や渡航に基づくワクチン接種の急増は、移住者の流入や大規模な国際イベントが開催される国で見られます。ワクチンで予防可能な病気に対する認識が向上し、世界の予防接種資金が増加するにつれ、公的・私的両方のヘルスケアシステムがおたふくかぜ対策に力を入れるようになっています。

おたふくかぜワクチン市場の成長はいくつかの要因によって牽引...

おたふくかぜワクチン市場の成長は、世界の予防接種活動の増加、人口の多い地域でのおたふくかぜの再流行、おたふくかぜに関連する合併症の認知拡大など、いくつかの要因によって牽引されています。ワクチン製剤、コールドチェーンロジスティクス、株最適化における技術的進歩により、有効性とアクセシビリティの両方が向上しています。小児・思春期医療への投資の増加、サーベイランス基盤の強化、国の予防接種ガイドラインの更新も需要を支えています。ヘルスケアシステムが感染症への備えとワクチンの普遍的な接種を優先していることから、おたふくかぜワクチン市場は先進国、新興経済諸国ともに持続的な成長を遂げるものと思われます。

セグメント

製品タイプ（1価、混合、2価、3価、その他の製品タイプ）;エンドユーザー（小児科クリニック、病院、NGO、その他のエンドユーザー）

調査対象企業の例（注目の合計42社）

  • Bharat Biotech
  • Bio Farma
  • China Bio-Immunity Corporation
  • GlaxoSmithKline plc（GSK）
  • Haffkine Bio-Pharmaceutical Corp.
  • Indian Immunologicals Ltd.
  • Instituto Butantan
  • Kitasato Daiichi Sankyo Vaccine Co., Ltd.
  • LG Chem
  • Merck & Co., Inc.
  • Microgen
  • Panacea Biotec Ltd.
  • Sanofi Pasteur
  • Serum Institute of India Pvt. Ltd.
  • Shanghai Institute of Biological Products
  • Sinovac Biotech Ltd.
  • Takeda Pharmaceutical Company Ltd.
  • The Research Institute for Biological Safety Problems
  • Torii Pharmaceutical Co., Ltd.
  • Zydus Lifesciences Ltd.

AIインテグレーション

私たちは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP35401

Global Mumps Vaccines Market to Reach US$993.5 Million by 2030

The global market for Mumps Vaccines estimated at US$650.5 Million in the year 2024, is expected to reach US$993.5 Million by 2030, growing at a CAGR of 7.3% over the analysis period 2024-2030. Monovalent, one of the segments analyzed in the report, is expected to record a 9.0% CAGR and reach US$483.5 Million by the end of the analysis period. Growth in the Combinational segment is estimated at 4.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$177.2 Million While China is Forecast to Grow at 11.7% CAGR

The Mumps Vaccines market in the U.S. is estimated at US$177.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$212.6 Million by the year 2030 trailing a CAGR of 11.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.5% and 7.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.9% CAGR.

Global Mumps Vaccines Market - Key Trends & Drivers Summarized

Why Are Mumps Vaccines Critical to Global Public Health Strategies?

Mumps vaccines play a pivotal role in preventing outbreaks of mumps, a contagious viral disease characterized by swelling of the salivary glands, fever, headache, and in some cases, complications such as meningitis, orchitis, and hearing loss. The vaccine-commonly administered as part of the MMR (measles, mumps, and rubella) combination-has significantly reduced global mumps incidence since its introduction. However, recent outbreaks, even in highly vaccinated populations, have reignited the focus on improving coverage and long-term immunity.

Routine immunization programs in many countries include the mumps vaccine as a two-dose schedule during early childhood, often reinforced with booster doses in adolescence or adulthood in outbreak-prone regions. Because of its role in broader viral containment strategies, the mumps vaccine is not only critical for individual protection but also essential for maintaining community-level herd immunity-particularly in schools, universities, military installations, and other high-density environments.

How Are Vaccine Technologies Evolving to Address Efficacy and Coverage Challenges?

Most mumps vaccines in use today are live attenuated virus formulations, primarily derived from strains such as Jeryl Lynn, Leningrad-Zagreb, or Urabe. While effective, these strains exhibit varying immunogenicity and duration of protection, which can influence long-term effectiveness and population-level outbreak resilience. As a result, research is ongoing into improving vaccine efficacy through new attenuation techniques, strain modification, and enhanced adjuvant systems.

Some public health authorities are also exploring the development of monovalent or bivalent boosters to augment mumps-specific immunity, especially in populations experiencing waning antibody levels. Efforts to develop thermostable formulations and intranasal delivery systems are under way to improve vaccine uptake in low-resource settings. Moreover, genomic surveillance is being used to monitor circulating mumps strains and assess vaccine-strain match, helping update recommendations and refine immunization schedules.

Which Regions and Demographic Groups Are Driving Market Demand?

High-income countries with established immunization programs continue to drive demand for MMR vaccines, particularly through pediatric schedules and school-entry requirements. However, adult booster programs are expanding in response to mumps outbreaks in universities and healthcare settings. In emerging economies, efforts to scale up routine immunization coverage are boosting primary demand for the MMR vaccine, including in parts of South Asia, Sub-Saharan Africa, and Latin America.

Populations in conflict zones or regions with disrupted healthcare infrastructure are also priority targets for mumps vaccination through international aid and mass immunization campaigns. Seasonal and travel-based vaccination spikes are seen in countries that experience migratory influxes or host large international events. As awareness of vaccine-preventable diseases improves and global immunization funding increases, both public and private healthcare systems are intensifying their focus on mumps control.

The Growth in the Mumps Vaccines Market Is Driven by Several Factors…

The growth in the mumps vaccines market is driven by several factors including increasing global immunization efforts, resurgence of mumps outbreaks in highly populated areas, and expanded awareness of complications associated with the disease. Technological advances in vaccine formulation, cold chain logistics, and strain optimization are improving both efficacy and accessibility. Rising investments in pediatric and adolescent health, enhanced surveillance infrastructure, and updated national immunization guidelines are also supporting demand. As healthcare systems prioritize infectious disease preparedness and universal vaccine coverage, the mumps vaccine market is set for sustained growth across both developed and developing economies.

SCOPE OF STUDY:

The report analyzes the Mumps Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Monovalent, Combinational, Divalent, Trivalent, Other Product Types); End-Use (Pediatric Clinics, Hospitals, NGOs, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

  • Bharat Biotech
  • Bio Farma
  • China Bio-Immunity Corporation
  • GlaxoSmithKline plc (GSK)
  • Haffkine Bio-Pharmaceutical Corp.
  • Indian Immunologicals Ltd.
  • Instituto Butantan
  • Kitasato Daiichi Sankyo Vaccine Co., Ltd.
  • LG Chem
  • Merck & Co., Inc.
  • Microgen
  • Panacea Biotec Ltd.
  • Sanofi Pasteur
  • Serum Institute of India Pvt. Ltd.
  • Shanghai Institute of Biological Products
  • Sinovac Biotech Ltd.
  • Takeda Pharmaceutical Company Ltd.
  • The Research Institute for Biological Safety Problems
  • Torii Pharmaceutical Co., Ltd.
  • Zydus Lifesciences Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Mumps Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Mumps Outbreaks in Vaccinated Populations Drives Booster Dose Recommendations
    • Increased Global Immunization Coverage Supports Continued Demand for MMR and MMRV Combination Vaccines
    • OEM Focus on Enhancing Immunogenicity and Long-Term Protection Improves Vaccine Formulations
    • Push for School and Workplace Immunization Requirements Sustains High Uptake of Mumps Vaccines
    • WHO and UNICEF Procurement Programs Expand Access in Developing Regions Through Gavi Partnerships
    • Growth in Travel and International Student Populations Spurs Pre-Travel Mumps Immunization Demand
    • OEM Development of Thermostable and Liquid Vaccine Formats Enhances Cold Chain Resilience
    • Increased Surveillance and Epidemiological Tracking Improve Targeting of High-Risk Populations
    • Rising Demand for Two-Dose and Catch-Up Immunization Schedules Strengthens Booster Market
    • Global Push for Measles and Rubella Elimination Encourages Ongoing Inclusion of Mumps in Combination Shots
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Mumps Vaccines Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Mumps Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Mumps Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Mumps Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Monovalent by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Monovalent by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Monovalent by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Combinational by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Combinational by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Combinational by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Divalent by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Divalent by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Divalent by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Trivalent by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Trivalent by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Trivalent by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Pediatric Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Pediatric Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Pediatric Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for NGOs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for NGOs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for NGOs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Mumps Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Mumps Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Mumps Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 53: China Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: China 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Mumps Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Mumps Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Mumps Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Mumps Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Mumps Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 65: France Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 68: France Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: France 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Mumps Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Germany 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Italy 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Mumps Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 83: UK Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 86: UK Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: UK 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Spain 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 92: Spain Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Spain Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Spain 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Russia 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 98: Russia Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Russia Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Russia 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Europe Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Rest of Europe 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Mumps Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Mumps Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Mumps Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Mumps Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Asia-Pacific 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Mumps Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Australia 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 119: Australia Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Australia Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Australia 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • Mumps Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 122: India Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: India 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 125: India Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: India Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: India 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: South Korea 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 131: South Korea Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: South Korea Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: South Korea 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Asia-Pacific Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Asia-Pacific 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Mumps Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Mumps Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Mumps Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Mumps Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Latin America 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Latin America 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Argentina 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 152: Argentina Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Argentina Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Argentina 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Brazil 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 158: Brazil Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Brazil Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Brazil 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Mexico 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 164: Mexico Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Mexico Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Mexico 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Rest of Latin America Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Rest of Latin America 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Mumps Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Mumps Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Mumps Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Mumps Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Middle East 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Iran 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 185: Iran Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Iran Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Iran 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Israel 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 191: Israel Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Israel Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Israel 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Saudi Arabia Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Saudi Arabia 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: UAE 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 203: UAE Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: UAE Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: UAE 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Rest of Middle East Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Rest of Middle East 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • Mumps Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Mumps Vaccines by Product Type - Monovalent, Combinational, Divalent, Trivalent and Other Product Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: Africa 15-Year Perspective for Mumps Vaccines by Product Type - Percentage Breakdown of Value Sales for Monovalent, Combinational, Divalent, Trivalent and Other Product Types for the Years 2015, 2025 & 2030
    • TABLE 215: Africa Recent Past, Current & Future Analysis for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Africa Historic Review for Mumps Vaccines by End-Use - Pediatric Clinics, Hospitals, NGOs and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: Africa 15-Year Perspective for Mumps Vaccines by End-Use - Percentage Breakdown of Value Sales for Pediatric Clinics, Hospitals, NGOs and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION